up and coming crypto currencies People searches

Hunan procuratorate prosecuted Wang Yonghong for alleged bribery and abuse of power according to law. Recently, the case of Wang Yonghong (deputy department level), former member of the Standing Committee of Shaoyang Municipal Committee of Hunan Province and former executive deputy mayor of the Municipal People's Government, was assigned jurisdiction by Hunan Provincial People's Procuratorate, and Loudi Municipal People's Procuratorate prosecuted Loudi Intermediate People's Court according to law. The case is being further processed. At the stage of examination and prosecution, the procuratorial organ informed the defendant Wang Yonghong of his litigation rights according to law, interrogated the defendant according to law and listened to the opinions of defenders. Loudi City People's Procuratorate sued the accusation that the defendant Wang Yonghong, as a national staff member, used his position to seek benefits for others and illegally accepted other people's property, with a huge amount; As a staff member of a state organ, he abuses his power, causing great losses to the interests of the state and the people. According to law, he should be investigated for criminal responsibility for accepting bribes and abusing his power.CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.Turkish Foreign Minister Fidan discussed the situation in Syria and Gaza with US Secretary of State Blinken. Turkish Foreign Minister Fidan: We discussed the possible roles of Turkey and the United States in Syria in the future. Our primary task is to ensure the stability of Syria and prevent extremist organizations "Islamic State" and the PKK from taking control of Syria.

Wuzhong, Jiangsu; Dobutamine Hydrochloride Injection and Paramivir Injection are planned to win the bid for the national centralized drug procurement. Jiangsu Wuzhong announced that in the national centralized drug procurement, the bid price of Dobutamine Hydrochloride Injection and Paramivir Injection is 3.58 yuan and 7.47 yuan respectively. The procurement cycle of the two products is until December 31, 2027, and they are supplied to Fujian, Anhui, Jilin, Hubei, Beijing, Inner Mongolia and other provinces and cities respectively. Winning the bid will help to expand the sales of related products, improve market share and brand influence, and have a positive impact on the company's future business performance.On the 13th, glass fell by 2.14%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract glass closed at 2505, up or down by -2.14%, with a turnover of 671,300 lots. The position data showed that the top 20 seats were clear, and the difference position was 46,081 lots. The total turnover of glass futures contracts was 999,900 lots, an increase of 189,100 lots over the previous day. The first 20 seats in the contract held 565,600 lots, a decrease of 12,000 lots from the previous day. The short positions in the top 20 seats of the contract were 661,500 lots, a decrease of 13,600 lots from the previous day. (Sina Futures)Citigroup: The target price of Illumina is lowered from $190 to $165, and the rating is lowered from "buy" to "neutral".

Spain's CPI monthly rate in November was 0.2%, expected to be 0.2%, and the previous value was 0.20%. Spain's CPI annual rate in November ended at 2.4%, with an expected 2.4% and a previous value of 2.40%. Spain reconciled CPI monthly rate in November with the final value of 0%, the expected value of 0% and the previous value of 0.00%. Spain's November harmonized CPI annual rate ended at 2.4%, with an expected 2.4% and a previous value of 2.40%.On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.